• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Future of the GLP-1 Receptor Agonists.

作者信息

Hirsch Irl B

机构信息

Division of Metabolism, Endocrinology, and Nutrition, University of Washington School of Medicine, Seattle.

出版信息

JAMA. 2019 Apr 16;321(15):1457-1458. doi: 10.1001/jama.2019.2941.

DOI:10.1001/jama.2019.2941
PMID:30903797
Abstract
摘要

相似文献

1
The Future of the GLP-1 Receptor Agonists.胰高血糖素样肽-1受体激动剂的未来
JAMA. 2019 Apr 16;321(15):1457-1458. doi: 10.1001/jama.2019.2941.
2
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.在接受胰高血糖素样肽-1 受体激动剂利拉鲁肽治疗的基础上联合应用二肽基肽酶-4 抑制剂西格列汀治疗 2 型糖尿病患者的随机对照试验。
Diabetes Obes Metab. 2017 Feb;19(2):200-207. doi: 10.1111/dom.12802. Epub 2016 Nov 9.
3
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.度拉糖肽：用于治疗2型糖尿病的最新胰高血糖素样肽-1受体激动剂。
Ann Pharmacother. 2015 Mar;49(3):351-9. doi: 10.1177/1060028014564180. Epub 2015 Jan 6.
4
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
Ann Intern Med. 2019 Aug 20;171(4):JC16. doi: 10.7326/ACPJ201908200-016.
5
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.在单独使用二甲双胍或磺酰脲类药物控制不佳的 2 型糖尿病成人中，额外口服司美格鲁肽对比西格列汀对糖化血红蛋白的影响：PIONEER 3 随机临床试验。
JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942.
6
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.长效胰高血糖素样肽-1 受体激动剂与艾塞那肽每日 2 次和西格列汀在 2 型糖尿病中的疗效和安全性比较：系统评价和荟萃分析。
Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.
7
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.对于日本2型糖尿病高血糖患者，在胰岛素单药治疗基础上加用西格列汀或二甲双胍，可通过对胰岛素和胰高血糖素分泌产生不同影响来改善血糖控制。
Endocr J. 2015;62(2):133-43. doi: 10.1507/endocrj.EJ14-0148. Epub 2014 Oct 19.
8
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.基于靶分子结合占有率评价 GLP-1 受体激动剂和 DPP-4 抑制剂的药物疗效。
Biol Pharm Bull. 2018;41(2):153-157. doi: 10.1248/bpb.b17-00237.
9
Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.口服胰高血糖素样肽受体激动剂（GLP1RA）咨询：与胰岛素咨询的比较。
Postgrad Med. 2020 Nov;132(8):663-666. doi: 10.1080/00325481.2020.1809906. Epub 2020 Oct 19.
10
GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.基于胰高血糖素样肽-1的疗法对2型糖尿病无微血管影响：一项急性和12周随机、双盲、安慰剂对照试验
Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2125-32. doi: 10.1161/ATVBAHA.116.307930. Epub 2016 Aug 25.

引用本文的文献

1
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.揭示胰高血糖素样肽-1的多方面作用：生理功能与治疗潜力
Toxicol Rep. 2025 Jan 16;14:101895. doi: 10.1016/j.toxrep.2025.101895. eCollection 2025 Jun.
2
Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist on Outcomes Following Major Surgery.术前胰高血糖素样肽-1受体激动剂对大手术后结局的影响。
World J Surg. 2025 Mar;49(3):698-707. doi: 10.1002/wjs.12484. Epub 2025 Jan 9.
3
Treatment of Hypothalamic Obesity With GLP-1 Analogs.使用胰高血糖素样肽-1类似物治疗下丘脑性肥胖。
J Endocr Soc. 2024 Nov 14;9(1):bvae200. doi: 10.1210/jendso/bvae200. eCollection 2024 Nov 26.
4
Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.单体肽多激动剂慢性治疗诱导肥胖大鼠后，可减少食物摄入和体重。
Clin Nutr. 2024 Jul;43(7):1782-1790. doi: 10.1016/j.clnu.2024.05.035. Epub 2024 May 28.
5
Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.皮下注射司美格鲁肽治疗2型糖尿病患者的疗效和耐受性：一项更新的系统评价和荟萃分析。
Diabetol Metab Syndr. 2023 Oct 28;15(1):218. doi: 10.1186/s13098-023-01195-7.
6
Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon.下丘脑损伤患者的下丘脑性肥胖治疗：新药物即将面世。
Front Endocrinol (Lausanne). 2023 Sep 13;14:1256514. doi: 10.3389/fendo.2023.1256514. eCollection 2023.
7
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder.胰高血糖素样肽-1受体激动剂作为沃夫综合征1型谱系障碍中有前景的疾病修饰药物。
Front Clin Diabetes Healthc. 2023 Jun 2;4:1171091. doi: 10.3389/fcdhc.2023.1171091. eCollection 2023.
8
Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.金雀花堿，一种有潜力的口服小分子胰高血糖素样肽-1 受体激动剂，可降低血糖并改善非酒精性脂肪性肝炎。
Drug Des Devel Ther. 2023 May 11;17:1417-1432. doi: 10.2147/DDDT.S404055. eCollection 2023.
9
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.GLP-1 受体激动剂治疗肥胖症：一种有前途的方法。
Front Endocrinol (Lausanne). 2023 Feb 1;14:1085799. doi: 10.3389/fendo.2023.1085799. eCollection 2023.
10
GLP-1 receptor agonist as a modulator of innate immunity.GLP-1 受体激动剂作为先天免疫调节剂。
Front Immunol. 2022 Dec 8;13:997578. doi: 10.3389/fimmu.2022.997578. eCollection 2022.